| The role and impact of SNPs in pharmacogenomics and personalized medicine. | |
| | |
MedLine Citation:
|
PMID: 21453271 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Over 10 million SNPs have been discovered to date as the result of both a private and public effort in the past two decades. Extensive investigations on SNPs have been performed to assess clinical applications for pharmacogenomics and Personalized Medicine. Recently, around the 10(th) anniversary of the first publication by the Human Genome Project, Hamburg and Collins addressed questions regarding the progress of the genomics field and its impact on pharmacogenomics / Personalized Medicine. Similar questions remain around the potential link of SNPs to Personalized Medicine applications, and the extent to which they have impacted "real world" clinical practices. Built upon these previous efforts, and to achieve our objectives of describing and assessing the role of SNPs and their impact on Personalized Medicine, this article analyzes and summarizes the clinical relevance, molecular mechanisms, clinical evidence, and preliminary regulatory and clinical guideline information of relevant SNPs. In addition, it focuses on two applications directly related to Personalized Medicine drug therapeutics: predictive biomarkers for patient stratification and dose selection. In summary, this article attempts to provide a general and comprehensive view of the role of SNPs in pharmacogenomics and Personalized Medicine, as well as a practical view of their impact on clinical practice today. |
| | |
Authors:
|
Rachel E Laing; Patricia Hess; Yingjie Shen; Jian Wang; Sean X Hu |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current drug metabolism Volume: 12 ISSN: 1875-5453 ISO Abbreviation: Curr. Drug Metab. Publication Date: 2011 Jun |
Date Detail:
|
Created Date: 2011-06-07 Completed Date: 2011-09-28 Revised Date: 2012-01-19 |
Medline Journal Info:
|
Nlm Unique ID: 100960533 Medline TA: Curr Drug Metab Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 460-86 Citation Subset: IM |
Affiliation:
|
Bionest Partners, New York, NY 10005, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Biomarkers, Pharmacological* Cardiovascular Diseases / drug therapy, genetics Central Nervous System Diseases / drug therapy, genetics Clinical Trials as Topic Communicable Diseases / drug therapy, genetics Databases, Genetic Drug Labeling Drug Therapy / methods* Eye Diseases / drug therapy, genetics Humans Individualized Medicine / methods* Inflammation / drug therapy, genetics Metabolic Diseases / drug therapy, genetics Neoplasms / drug therapy, genetics Pharmaceutical Preparations / metabolism Pharmacogenetics / methods* Polymorphism, Single Nucleotide / genetics* Practice Guidelines as Topic |
| Chemical | |
Reg. No./Substance:
|
0/Biomarkers, Pharmacological; 0/Pharmaceutical Preparations |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibi...
Next Document: Advances in human cytochrome p450 and personalized medicine.